日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Tumorigenesis promotes Mdm4-S overexpression

肿瘤发生促进Mdm4-S过表达

Vinod Pant, Connie A Larsson, Neeraj Aryal, Shunbin Xiong, M James You, Alfonso Quintas-Cardama, Guillermina Lozano

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL

Eμ-TCL1 小鼠模型中,p53 独立的伊布替尼反应证实其对高风险 CLL 有效

H J Lee, M Gallardo, H Ma, X Zhang, C A Larsson, A Mejia, M J Hornbaker, Y Qi, X Su, L R Pageon, A Quintas-Cardama, S M Post

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

外周血原始细胞清除是急性髓系白血病诱导化疗后生存和疗效的独立预后因素

Short, Nicholas J; Benton, Christopher B; Chen, Hsiang-Chun; Qiu, Peng; Gu, Lisa; Pierce, Sherry; Brandt, Mark; Maiti, Abhishek; Min, Taejin L; Naqvi, Kiran; Quintas-Cardama, Alfonso; Konopleva, Marina; Kadia, Tapan; Cortes, Jorge; Garcia-Manero, Guillermo; Ravandi, Farhad; Jabbour, Elias; Kantarjian, Hagop; Andreeff, Michael

hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies

hnRNP K 是一种单倍体不足的肿瘤抑制因子,可调节血液系统恶性肿瘤的增殖和分化程序

Miguel Gallardo, Hun Ju Lee, Xiaorui Zhang, Carlos Bueso-Ramos, Laura R Pageon, Mark McArthur, Asha Multani, Aziz Nazha, Taghi Manshouri, Jan Parker-Thornburg, Inmaculada Rapado, Alfonso Quintas-Cardama, Steven M Kornblau, Joaquin Martinez-Lopez, Sean M Post

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase

酪氨酸激酶抑制剂作为慢性粒细胞白血病加速期患者的初始治疗

Ohanian, Maro; Kantarjian, Hagop M; Quintas-Cardama, Alfonso; Jabbour, Elias; Abruzzo, Lynne; Verstovsek, Srdan; Borthakur, Gautam; Ravandi, Farhad; Garcia-Manero, Guillermo; Champlin, Richard; Pierce, Sherry; Alattar, Mona Lisa; Trinh, Long Xuan; Luthra, Raja; Ferrajoli, Alessandra; Kadia, Tapan; O'Brien, Susan; Cortes, Jorge E

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

患者自主停用酪氨酸激酶抑制剂:单中心经验

Benjamini, Ohad; Kantarjian, Hagop; Rios, Mary Beth; Jabbour, Elias; O'Brien, Susan; Jain, Preetesh; Cardenas-Turanzas, Marylou; Faderl, Stefan; Garcia-Manero, Guillermo; Ravandi, Farhad; Borthakur, Gautam; Quintas-Cardama, Alfonso; Cortes, Jorge

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

免疫调节剂和PP2A激活药物FTY720(芬戈莫德,Gilenya)在JAK2驱动的血液系统恶性肿瘤中的拮抗活性

Oaks, Joshua J; Santhanam, Ramasamy; Walker, Christopher J; Roof, Steve; Harb, Jason G; Ferenchak, Greg; Eisfeld, Ann-Kathrin; Van Brocklyn, James R; Briesewitz, Roger; Saddoughi, Sahar A; Nagata, Kyosuke; Bittman, Robert; Caligiuri, Michael A; Abdel-Wahab, Omar; Levine, Ross; Arlinghaus, Ralph B; Quintas-Cardama, Alfonso; Goldman, John M; Apperley, Jane; Reid, Alistair; Milojkovic, Dragana; Ziolo, Mark T; Marcucci, Guido; Ogretmen, Besim; Neviani, Paolo; Perrotti, Danilo

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

对于3个月时未出现主要细胞遗传学反应的慢性粒细胞白血病患者,可能需要在6个月时进行评估。

Nazha, Aziz; Kantarjian, Hagop; Jain, Preetesh; Romo, Carlos; Jabbour, Elias; Quintas-Cardama, Alfonso; Luthra, Raja; Abruzzo, Lynne; Borthakur, Gautam; Ravandi, Farhad; Pierce, Sherry; O'Brien, Susan; Cortes, Jorge

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

鲁索替尼治疗骨髓纤维化患者血细胞减少症的管理及剂量调整对疗效的影响

Verstovsek, Srdan; Gotlib, Jason; Gupta, Vikas; Atallah, Ehab; Mascarenhas, John; Quintas-Cardama, Alfonso; Sun, William; Sarlis, Nicholas J; Sandor, Victor; Levy, Richard S; Kantarjian, Hagop M; Mesa, Ruben A

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

泊马度胺对伴有严重贫血的骨髓纤维化患者疗效有限

Daver, Naval; Shastri, Aditi; Kadia, Tapan; Quintas-Cardama, Alfonso; Jabbour, Elias; Konopleva, Marina; O'Brien, Susan; Pierce, Sherry; Zhou, Lingsha; Cortes, Jorge; Kantarjian, Hagop; Verstovsek, Srdan